350 FIFTH AVENUE, NEW YORK, NY
Directors Elected at Daxor Corporation Annual Meeting; Voting Results Disclosed
Daxor Corporation Enters Definitive Securities Purchase Agreement for $8.14M
Other Events
Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Shareholder votes
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
FY 2011
Q3
Q2 amended
Q2
Q1
FY 2010
Prospectus filed pursuant to Rule 424(b)(4)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
SEC Form 25 - Delisting Notification
Certificate
Registration of Securities
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Certified Shareholder Report
Annual Report of Proxy Voting Record
Form N-PORT - Public Monthly Portfolio Investments Report
Amended Investment Company Act Rule 8f-2 Notice
NT NPORT-P
Semi-Annual Financial Report for Management Investment Companies